Phase 4
Completed N=291
Efficacy and Safety of Single, Low-dose Dexamethasone in Patients After Total Knee Arthroplasty
Osteoarthritis, Knee
Source: ClinicalTrials.gov NCT01612702 ↗
Enrolled (actual)
291
Serious AEs
0.7%
Results posted
May 2013
Primary outcomePrimary: Incidence of Nausea and Vomiting — 24; 40 percentage of participant
Summary
This study was conducted to determine the efficacy of an additional preemptive, single, low-dose dexamethasone in terms of incidence and severity of postoperative nausea/vomiting (PONV), pain level, and the safety in terms of wound complications in patients managed with our antiemetic protocol based on Ramosetron following TKA.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Nausea and Vomiting |
24; 40 | — |
| SECONDARY Pain Level |
2.4; 4.0 | — |
| SECONDARY Wound Complication |
1; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of primary osteoarthritis, knee
- Scheduled for elective total knee arthroplasty
- Signed written informed consent
Exclusion Criteria
- Refusing participate
- Contraindication to regional anesthesia
- Severe impairment of bowel motility
- administration of other antiemetic drug within 24hours before surgery
- systemic steroid within 24hours before surgery
- history of cardiovascular & respiratory disease
- renal & hepatic failure
Data sourced from ClinicalTrials.gov (NCT01612702). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.